Everything below concerns somatotroph. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Last reviewed on 2026-01-17. Where a claim depends on a specific study, the study is described rather than over-claimed.
Binding of the peptide to the growth hormone-releasing hormone receptor on pituitary somatotrophs triggers a G protein coupled cascade that raises cyclic AMP and opens calcium channels. The result is greater secretion of growth hormone into the bloodstream. Because the peptide acts at the same receptor as the natural hypothalamic hormone, its effect is amplified pulse size rather than an entirely separate release pathway. Receptor binding alone does not determine the response, since somatostatin tone and other inputs modulate the final output.
The albumin-binding version stays in circulation for days, because covalent attachment to serum albumin shields the peptide from rapid filtration and degradation. Reported half-lives for this form fall in the range of several days. The version without the linker is cleared in minutes, with estimates often near thirty minutes in animal work. These figures come from small studies and vary with assay method, species, and route, so they are best read as approximate rather than fixed constants.
Studies in this area generally track growth hormone pulses, insulin-like growth factor 1 concentrations, and occasionally body composition endpoints. Most published human data come from early, small trials, and questions about long-term effects remain open. Whether repeated exposure alters pituitary responsiveness over time is not settled. Analytical work relies on immunoassays for the hormones and on mass spectrometry for the peptide itself, because the two measurements answer different questions.
CJC-1295 is a synthetic peptide analog of growth hormone-releasing hormone, constructed on the 29-amino-acid fragment designated GRF(1-29). The name began as an internal development code during the 1990s and later spread through research supply catalogs and discussion forums. The molecule does not occur in nature; its sequence is engineered rather than isolated from tissue. Two related compounds are sold under this single label, and they differ by one appended chemical group that strongly influences how long the peptide remains in circulation.
The dividing feature between the two forms is a maleimide-based drug affinity complex, abbreviated DAC. In the DAC-bearing version, a linker attaches the peptide to serum albumin after administration, and that association slows removal from plasma. The version lacking DAC appears in catalogs as MOD GRF(1-29) or tetrasubstituted GRF(1-29). Because informal writing treats both as one item, comparisons drawn from such sources routinely blend measurements taken from two molecules with substantially different behavior.
| Property | Value | Notes |
|---|---|---|
| Target receptor | GHRH receptor (GHRHR) | Expressed on pituitary somatotrophs |
| Primary action | Stimulates growth hormone release | Amplifies pulse size |
| Half-life, albumin-binding form | Several days as reported | Slow release from albumin complex |
| Half-life, unmodified analog | About 30 minutes in animal estimates | Cleared by proteases and filtration |
| Common analytical approach | LC-MS/MS for peptide, immunoassay for hormones | Methods answer different questions |
CJC-1295 belongs to a family of synthetic peptides modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. The compound is built from the first twenty-nine amino acids of the natural human sequence, a fragment that retains full receptor binding capacity. Native growth hormone-releasing hormone is degraded quickly in circulation, so the fragment alone has limited practical value. Early work therefore focused on chemical modifications that preserve receptor binding while slowing enzymatic breakdown. The result is a molecule described in the literature as a long-acting analog of the natural hormone.
Two forms circulate under the CJC-1295 name, and they differ by a single appended group. The version without a drug affinity complex carries four substitutions along the peptide chain, including a D-alanine near the amino terminus and replacements at three other positions. These changes block the enzyme dipeptidyl peptidase IV and remove a methionine residue that is prone to oxidation. The modified fragment is frequently labeled MOD GRF 1-29. Naming conventions are inconsistent across informal sources, which is a common source of confusion.
CJC-1295 is a synthetic peptide modeled on growth hormone-releasing hormone, the hypothalamic signal that prompts the pituitary to release growth hormone. Its sequence corresponds to the first twenty-nine residues of human GHRH, with four substitutions that slow enzymatic breakdown. Early descriptions placed the compound in research on growth hormone deficiency and related conditions, and later literature groups it with the long-acting GHRH analogs. The name appears in both laboratory and popular fitness writing, where it sometimes labels chemically different peptides.
Two related peptides circulate under the CJC-1295 label, and they differ mainly in how long they persist in circulation. The version carrying a drug affinity complex includes a maleimidopropionic acid linker that forms a covalent bond with serum albumin. The other version, usually written as modified GRF(1-29) or tetrasubstituted GRF(1-29), lacks that linker and is cleared quickly. Mixing the two produces inconsistent readings of published half-life values, because the linker rather than the receptor-facing sequence drives most of the difference.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
Another use of depleted uranium is in kinetic energy penetrators, anti-armor rounds such as the 120 mm sabot rounds fired from the British Challenger 1 and Challenger 2, as well as the American M1A1 and M1A2 Abrams. Kinetic energy penetrator rounds consist of a long, relatively thin penetrator surrounded by a discarding sabot. Staballoys are metal alloys of depleted uranium with a very small proportion of other metals, usually titanium or molybdenum. One formulation has a composition of 99.25% by mass of depleted uranium and 0.75% by mass of titanium. Staballoys are approximately 1.67 times as dense as lead and are designed for use in kinetic energy penetrator armor-piercing ammunition. The US Army uses DU in an alloy with around 3.5% titanium. Depleted uranium is favored for the penetrator because it is self-sharpening and flammable. On impact with a hard target, such as an armored vehicle, the tip of the projectile will be "mushroomed", while the back of the projectile is still a rigid solid. This leads to adiabatic shearing, and together with the spin of the projectile results in a shedding of the mushroomed plastic phase in such a way that it forms a new sharp tip. This shedding of the mushroomed tip improves penetration properties compared to the complete dispersal that takes place with tungsten penetrators, therefore DU penetrators are 20% more effective than tungsten rounds. The impact and subsequent release of heat energy causes it to ignite when in contact with oxygen.
== Subfamily B3 == Subfamily B3 includes Methuselah and other Drosophila proteins. Other than the typical seven-transmembrane region, characteristic structural features include an amino-terminal extracellular domain involved in ligand binding, and an intracellular loop (IC3) required for specific G-protein coupling.
Bully: Kevin Garcia Height: 5'11 Weight: 175 lbs. Victim(s): Anthony (co-worker) and Sam Fighter: Tyron Woodley Height: 5'9 Weight: 182 lbs. Money earned by Bully: $1,000 Money earned by victim(s): $9,000 Original airing:
Sources: en.wikipedia.org
In 2009, IGN named Newell one of the top 100 game creators, writing that it was "almost impossible to gauge" Valve's influence on game design, technology and the video games industry. In December 2010, Forbes listed Newell as "A Name You Need to Know", primarily for his work on Steam and partnerships with multiple major developers. In 2013, Newell was added to the Academy of Interactive Arts & Sciences Hall of Fame and received the BAFTA Fellowship for his contributions to the video game industry. According to Josh Weier, the project lead for Portal 2 (2011), Newell became less involved in game development after Portal 2 as many developers would blindly agree with his ideas due to his position. As of 2024, Newell had become less involved in Valve and was spending more time on personal projects.
== Clinical significance == Hepatokines can serve as biomarkers and are potential therapeutic targets for metabolic diseases. The liver through execretion of hepatokines regulates the whole bodies metabolism in response to stress signals. Secreted hepatokines in response to exercise induce favorable metabolic changes in fat, blood vessels, and skeletal muscle that can reduce metabolic diseases. Although substantial progress has been made in understanding disease-controlled production of hepatokines, there is still so much to discover. There is so much room for discovery. For example, "little is known about the inductive mechanism of transcriptional reprogramming, protein translation, modification, and secretion of hepatokines, particularly through the ER and Golgi, and more. The identification and functional characterization of hepatokines may provide significant insights that could help in better understanding of MetS pathogenesis.
=== Microtox Omni software === The Microtox Omni software was developed by Azur Environmental and allows users of the Microtox Model 500 analyser to run tests, visualize data, calculate statistics and generate reports. This program contains a set of templates for all of the commonly used toxicity tests and allows you to modify or add to the provided templates. The modification of these templates allows for the production of new test formats not originally included with the software. The test templates that are included in this software define all of the parameters for a particular test method. This program calculates the most efficient way of setting up the desired test on the Model 500 Analyser. A test tutor is also included with Microsoft Omni that gives listed instructions on how to set up and run the test of interest. This software allows users to load files from previous versions of the Microtox DOS Software and also gives users the ability to save new data in that original format. A database is included in this software that grants users to access data from a number of other users and test sites, allowing for a comparison of data and trend changes over time. Microtox Omni can be used with any number of databases.
Sources: en.wikipedia.org
Reported values cluster in the range of several days, reflecting slow release from the albumin complex. Estimates differ across species and assay platforms. The figure describes circulation time in study settings rather than a fixed property.
Typical endpoints include growth hormone pulse frequency and amplitude, together with insulin-like growth factor 1 concentration. Some protocols add body composition or metabolic markers. Interpretation depends on baseline hormonal status, which varies widely between individuals.
Most human data come from small, early-stage studies, and independent replication is limited. Short-term effects on growth hormone release are documented; longer-term outcomes are not well characterized. Open questions include changes in pituitary responsiveness after repeated exposure.
No. It is a laboratory-synthesized analog built on a fragment of the natural hormone. The natural peptide is shorter-lived and lacks the stabilizing substitutions found in the synthetic version.